Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles
- PMID: 15824924
- DOI: 10.1007/s00775-005-0643-7
Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles
Abstract
The biological activity of N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones (aminoalkyl is 2-aminoethyl, 3-aminoprop-1-yl and 4-aminobut-1-yl) and their dinuclear platinum complexes has been evaluated in the U2-OS human osteosarcoma cell line and its cisplatin-resistant U2-OS/Pt subline. All the compounds have been found to exhibit high cytotoxicity in the sensitive cell line, and to overcome cisplatin resistance in U2-OS/Pt cells. Cellular processing of N,N'-bis(2-aminoethyl)-1,4-diaminoanthraquinone and the respective dinuclear platinum complex in the sensitive and resistant U2-OS cells has been studied over time using digital fluorescence microscopy. Cellular processing of the compounds has been found to be similar in sensitive and resistant U2-OS cells, which is in agreement with the lack of cross-resistance in the U2-OS/Pt cell line. Both the platinum complex and the free ligand quickly enter the cell and accumulate in the nucleus. The platinum complex is excreted from the cell via the Golgi apparatus, while the weakly basic anthraquinone ligand accumulates in the Golgi complex, where it is taken up by lysosomes and then transported to the cell surface. The cellular distribution of the fluorescent anthraquinones and their dinuclear platinum complexes in the sensitive/resistant pair of U2-OS osteosarcoma cell lines is compared with the earlier studied cellular processing in the sensitive/resistant pair of A2780 ovarian carcinoma cell lines. In the A2780cisR cell line, the platinum complexes (and not the free ligands) are sequestered in lysosomes, which is not the case in A2780 sensitive cells. The differences in cellular distribution of the compounds in these two sensitive/resistant pairs of cell lines most likely result from different resistance profiles in A2780cisR and U2-OS/Pt cells. Lysosomes of A2780cisR cells are less acidic than lysosomes of A2780 sensitive cells, which is likely to be the cause of a defect in endocytosis. The disruption of normal endocytosis might facilitate sequestration of the platinum complexes in lysosomes, which partly confers the cross-resistance of these complexes with cisplatin in the A2780cisR cell line. In contrast, sequestration in acidic vesicles does not occur in U2-OS/Pt cells that do not exhibit enhanced lysosomal pH and which are likely to have normal endocytosis.
Similar articles
-
Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells.J Biol Inorg Chem. 2004 Jun;9(4):403-13. doi: 10.1007/s00775-004-0539-y. Epub 2004 Apr 8. J Biol Inorg Chem. 2004. PMID: 15071767
-
Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance.J Biol Inorg Chem. 2004 Jun;9(4):414-22. doi: 10.1007/s00775-004-0540-5. Epub 2004 Apr 8. J Biol Inorg Chem. 2004. PMID: 15071768
-
Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs.J Med Chem. 2005 Aug 11;48(16):5191-202. doi: 10.1021/jm050216h. J Med Chem. 2005. PMID: 16078838
-
[Drug discovery research in in-vivo antitumor-active azolato-bridged dinuclear Pt(II) complexes].Yakugaku Zasshi. 2012;132(3):253-9. doi: 10.1248/yakushi.132.253. Yakugaku Zasshi. 2012. PMID: 22382827 Review. Japanese.
-
Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin.Cancer Invest. 1993;11(5):578-89. doi: 10.3109/07357909309011676. Cancer Invest. 1993. PMID: 8402226 Review.
Cited by
-
NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs.Chem Sci. 2014 Jun 6;5(8):3135-3143. doi: 10.1039/c3sc53426j. eCollection 2014 Jun 30. Chem Sci. 2014. PMID: 35919909 Free PMC article.
-
Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney.Chem Sci. 2016 May 1;7(5):3052-3061. doi: 10.1039/c5sc04383b. Epub 2016 Feb 3. Chem Sci. 2016. PMID: 29997796 Free PMC article.
-
Confocal fluorescence microscopy studies of a fluorophore-labeled dirhodium compound: visualizing metal-metal bonded molecules in lung cancer (A549) cells.J Am Chem Soc. 2014 Jun 4;136(22):7861-4. doi: 10.1021/ja503774m. Epub 2014 May 22. J Am Chem Soc. 2014. PMID: 24854400 Free PMC article.
-
Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.BMC Cancer. 2008 Jun 19;8:175. doi: 10.1186/1471-2407-8-175. BMC Cancer. 2008. PMID: 18565219 Free PMC article.
-
NanoSIMS multi-element imaging reveals internalisation and nucleolar targeting for a highly-charged polynuclear platinum compound.Chem Commun (Camb). 2013 Aug 11;49(62):6944-6. doi: 10.1039/c3cc42098a. Chem Commun (Camb). 2013. PMID: 23687657 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous